Japan, March 5 -- BIOSION INC has got intellectual property rights for 'ANTIBODY BINDING SIGLEC15 AND USES THEREOF.' Other related details are as follows:

Application Number: JP,2023-172391

Category (FI): A61K39/395@N,A61P19/10,A61P35/00,C07K16/28,C12N1/15,C12N1/19,C12N1/21,C12N15/13,C12N15/63@Z,C12N5/10,C12P21/08

Stage: PROBLEM TO BE SOLVED: To provide a therapeutic approach for cancer patients unresponsive to PD-1/PD-L1 targeting therapies.SOLUTION: Provided herein is an isolated monoclonal antibody that specifically binds human Siglec15, or an antigen-binding portion thereof. Also provided are a nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell, and a method for expressin...